Capital Cell, an investment company specialising in biotechnology and healthcare, and a member of CataloniaBio & HealthTech, has closed a €650K financing round with the aim of strengthening its international positioning. In 2023, the CNMV granted Capital Cell the authorisation to operate under European legislation in France, Germany, Italy, Portugal, the Netherlands, Belgium and Denmark.

Capital Cell has completed 50% of the financing round thanks to a loan from ENISA and the contribution of several business angels, such as entrepreneur John Bethell, founder of the medical recruitment company Wavelength. The rest of the round, €200k, has been closed through the investment platform SeedBlink with the aim of opening the company to investors across Europe. Daniel Oliver, CEO of Capital Cell, said: "Capital Cell's model, which has had a positive impact on the Spanish biotech ecosystem, is rapidly scalable. In order to have the same impact in other European countries, we want to strengthen our team and adapt the processes to the particularities of each market".

In its investment ecosystem, Capital Cell manages the first crowdfunding platform in Europe specialised in biomedicine/biotechnology and healthcare. Between 2015 and 2023, Capital Cell raised over €90 million in more than 100 financial rounds, and is one of the leading investors in biomedical innovation in Spain.

Last year continued to be a year of growth for the company as it raised more than €21K, which is 14% more than in 2022. The company helped a total of 17 startups to achieve their goals. The company is implementing its model in other European countries, with a permanent team in France and a partnership about to be closed in Italy.